Johnson & Johnson and BARDA to Fund ~$1B in Research and Development of Novel COVID-19 Vaccines

 Johnson & Johnson and BARDA to Fund ~$1B in Research and Development of Novel COVID-19 Vaccines

Additionally, J&J to establish new vaccine manufacturing capabilities in the US and production capacity outside the US to begin production of the vaccine, will enable to supply ~1B doses of vaccine globally

Shots:

  • The collaboration follows the existing partnership b/w J&J and BARDA while the company expects to initiate the clinical studies of selected vaccine candidates by Sept’2020 with the anticipated first batch of COVID-19 vaccine to be available for EUA in early 2021
  • Under the new agreement, J&J and BARDA to invest ~1B in research, development & clinical testing of vaccines. J&J will utilize its validated vaccine platform and allocating resources to focus the efforts
  • Additionally, J&J to establish new vaccine manufacturing capabilities in the US and production capacity outside the US to begin production of the vaccine, will enable to supply ~1B doses of vaccine globally

Click here ­to­ read full press release/ article | Ref: J&J | Image: Fierce Pharma

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post